Technical Support for the Implementation of Mass Drugs Administration with Triple Drugs Ivermectin, Diethylcarbamazine, and Albendazole (IDA) in Pekalongan City, Central Java Province, 2021
Request for Proposals (RFP) Bid Reference 015-2021 Unit Name NTD Unit-WHO Indonesia
Purpose of the RFP:
to enter into a contractual agreement with a successful bidder and select a suitable contractor to provide technical support for the implementation of MDA with triple drugs for LF Elimination Programme in Pekalongan City, 2020
Closing Date:
13 February 2021 at 10:00 Jakarta time
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419
2 Unit Name NTD Unit-WHO Indonesia
The World Health Organization (WHO) is seeking offers for Proposal. Your Company / Institution is invited to submit a proposal for the services in response to this Request for Proposals (RFP).
WHO is a public international organization, consisting of 194 Member States, and a Specialized Agency of the United Nations with the mandate to act as the directing and coordinating authority on international health work. As such, WHO is dependent on the budgetary and extra-budgetary contributions it receives for the implementation of its activities. Bidders are, therefore, requested to propose the best and most cost-effective solution to meet WHO requirements, while ensuring a high level of service.
1. Requirements WHO requires the successful bidder, to carry out Technical Support for the Implementation of Mass Drugs Administration with Triple Drugs Ivermectin, Diethylcarbamazine, and Albendazole (IDA) in Pekalongan City, 2020 . See attached detailed Terms of Reference for complete information.
The successful bidder shall be a for profit / not for profit institution operating in the field of public health with proven expertise in Neglected Tropical Diseases and/or lymphatic filariasis elimination programme.
Bidders should follow the instructions set forth below in the submission of their proposal to WHO.
2. Proposal The proposal and all correspondence and documents relating thereto shall be prepared and submitted in the English language.
The proposal should be concisely presented and structured to include the following information:
• Administrative documentation (2 to 4 pages): with names and addresses of institutions and/or consultants, team leader with CV, the experience and background of the institutions/consultants on the relevant topics (please complete Annex 2) • Proposed review organization (3 to 4 pages): include the objectives, methods, expected results and plan. • Proposed time line with the dates when the activity will be started and the deliverables can be achieved • Financial proposal must be prepared in IDR currency in line with the standard government rate as enclosed with component of professional fee, travels, meeting, field tests, recording videos, audios, and pictures.
Information which the bidder considers confidential, if any, should be clearly marked as such.
3. Instructions to Bidders Bidders must follow the instructions set forth in this RFP in the submission of their proposal to WHO.
A prospective bidder requiring any clarification on technical, contractual or commercial matters may notify WHO via email at the following address no later than seven working days prior to the closing date for the submission of offers: Email for submissions of all queries: [email protected] with cc to [email protected] (use Bid reference in subject line )
A consolidated document of WHO's responses to all questions (including an explanation of the query but without identifying the source of enquiry) will be sent to all prospective bidders who have received the RFP.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 2 3 Unit Name NTD Unit-WHO Indonesia
From the date of issue of this RFP to the final selection, contact with WHO officials concerning the RFP process shall not be permitted, other than through the submission of queries and/or through a possible presentation or meeting called for by WHO, in accordance with the terms of this RFP.
The bidder shall submit, in writing, the complete proposal to WHO, no later than 13 February 2021 at 10:00 hours Jakarta time (“the closing date”), as follows :
The submitted technical and financial proposal shall be in reference to the enclosed Terms of References and budget component.
A technical and financial proposal should be submitted separately in 2 emails stating in the subject the following reference number: RFP 015-2021.
Due to the current situation of COVID-19, submission of proposal can only be done electronically by email to: [email protected] (including any other email address in the submission will automatically disqualify the bid)
. All information and documentation related to the technical proposal (including the attached Annex 2: “Information about Bidders” shall be submitted to [email protected] stating in the email subject “Technical Proposal - RFP 015-2021”
. All information and documentation related to the financial proposal shall be submitted to [email protected] stating in the email subject “Financial Proposal - RFP 015-2021 ”.
PLEASE NOTE THAT ANY SUBMISSION OF FINANCIAL AND TECHNICAL TOGETHER IN 1 FILE WILL BE REJECTED.
Please make sure to include the following documents to ensure your submission is complete:
− A technical proposal, as described under part 2 above; − A financial proposal, as described under part 2 above; − Annex 2 (Vendor Information Form), duly completed and signed by a person or persons duly authorized to represent the bidder, to submit a proposal and to bind the bidder to the terms of this RFP. − Self-Declaration Form − Legal document for operation permit in Indonesia − Proposal Completeness Form
Each proposal shall be marked Ref: 015-2021 .
WHO may, at its own discretion, extend the closing date for the submission of proposals by notifying all bidders thereof in writing before the above closing date and time.
Any proposal received by WHO after the closing date for submission of proposals may be rejected. Bidders are therefore advised to ensure that they have taken all steps to submit their proposals in advance of the above closing date and time. The offer outlined in the proposal must be valid for a minimum period of 90 calendar days after the closing date. A proposal valid for a shorter period may be rejected by WHO. In exceptional circumstances, WHO may solicit the bidder’s consent to an extension of the period of validity. The request and the responses thereto shall be made in writing. Any bidder granting such an extension will not, however, be permitted to otherwise modify its proposal.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 3 4 Unit Name NTD Unit-WHO Indonesia
The bidder may withdraw its proposal any time after the proposal’s submission and before the above mentioned closing date, provided that written notice of the withdrawal is received by WHO at the email address indicated above, before the closing date for submission of proposals.
No proposal may be modified after its submission, unless WHO has issued an amendment to the RFP allowing such modifications.
No proposal may be withdrawn in the interval between the closing date and the expiration of the period of proposal validity specified by the bidder in the proposal (subject always to the minimum period of validity referred to above).
WHO may, at any time before the closing date, for any reason, whether on its own initiative or in response to a clarification requested by a (prospective) bidder, modify the RFP by written amendment. Amendments could, inter alia, include modification of the project scope or requirements, the project timeline expectations and/or extension of the closing date for submission.
All prospective bidders that have received the RFP will be notified in writing of all amendments to the RFP and will, where applicable, be invited to amend their proposal accordingly.
All bidders must adhere to the UN Supplier Code of Conduct, which is available on the WHO procurement website at http://www.who.int/about/finances-accountability/procurement/en/.
4. Evaluation Before conducting the technical and financial evaluation of the proposals received, WHO will perform a preliminary examination of these proposals to determine whether they are complete, whether any computational errors have been made, whether the documents have been properly signed, and whether the proposals are generally in order. Proposals which are not in order as aforesaid may be rejected.
The evaluation panel will evaluate the technical merits of all the proposals which have passed the preliminary examination of proposals based on the following weighting:
Technical Weighting: 70 % of total evaluation Financial Weighting: 30 % of total evaluation
Please note that WHO is not bound to select any bidder and may reject all proposals. Furthermore, since a contract would be awarded in respect of the proposal which is considered most responsive to the needs of the project concerned, due consideration being given to WHO’s general principles, including the principle of best value for money, WHO does not bind itself in any way to select the bidder offering the lowest price.
WHO may, at its discretion, ask any bidder for clarification of any part of its proposal. The request for clarification and the response shall be in writing. No change in price or substance of the proposal shall be sought, offered or permitted during this exchange.
NOTE: Individual contact between WHO and bidders is expressly prohibited both before and after the closing date for submission of proposals.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 4 5 Unit Name NTD Unit-WHO Indonesia
5. Award WHO reserves the right to: 1. Award the contract to a bidder of its choice, even if its bid is not the lowest; 2. Award separate contracts for parts of the work, components or items, to one or more bidders of its choice, even if their bids are not the lowest; 3. Accept or reject any proposal, and to annul the solicitation process and reject all proposals at any time prior to award of contract, without thereby incurring any liability to the affected bidder or bidders and without any obligation to inform the affected bidder or bidders of the grounds for WHO's action; 4. Award the contract on the basis of the Organization’s particular objectives to a bidder whose proposal is considered to be the most responsive to the needs of the Organization and the activity concerned; 5. Not award any contract at all.
WHO has the right to eliminate bids for technical or other reasons throughout the evaluation/selection process. WHO shall not in any way be obliged to reveal, or discuss with any bidder, how a proposal was assessed, or to provide any other information relating to the evaluation/selection process or to state the reasons for elimination to any bidder.
NOTE: WHO is acting in good faith by issuing this RFP. However, this document does not oblige WHO to contract for the performance of any work, nor for the supply of any products or services.
At any time during the evaluation/selection process, WHO reserves the right to modify the scope of the work, services and/or goods called for under this RFP. WHO shall notify the change to only those bidders who have not been officially eliminated due to technical reasons at that point in time.
WHO reserves the right at the time of award of contract to extend, reduce or otherwise revise the scope of the work, services and/or goods called for under this RFP without any change in the base price or other terms and conditions offered by the selected bidder.
WHO also reserves the right to enter into negotiations with one or more bidders of its choice, including but not limited to negotiation of the terms of the proposal(s), the price quoted in such proposal(s) and/or the deletion of certain parts of the work, components or items called for under this RFP.
Within 30 days of receipt of the contract between WHO and the successful bidder (the “Contract”), the successful bidder shall sign and date the Contract and return it to WHO according to the instructions provided at that time. If the bidder does not accept the Contract terms without changes, then WHO has the right not to proceed with the selected bidder and instead contract with another bidder of its choice. The Contract will include, without limitation, the provisions set forth in Annex 3.
Any and all of the contractor's (general and/or special) conditions of contract are hereby explicitly excluded from the Contract, i.e., regardless of whether such conditions are included in the Contractor's offer, or printed or referred to on the Contractor's letterhead, invoices and/or other material, documentation or communications.
We look forward to receiving your response to this RFP.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 5 6 Unit Name NTD Unit-WHO Indonesia
Yours sincerely,
NTD Unit – WHO Indonesia
Annexes
1. Detailed Term of Reference 2. Vendor Information Form 3. Contractual provisions 4. Budget Template and 2020 Government Standard Rate 5. Evaluation Criteria 6. Self-Declaration 7. Proposal Completeness Form
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 6 7 Unit Name NTD Unit-WHO Indonesia
Annex 1: Detailed Terms of Reference
Background Lymphatic Filariasis or elephantiasis is one of the neglected tropical diseases (NTDs). This disease is caused by filaria worms, transmitted by mosquitoes and spread throughout Indonesia. Disease-related disabilities may cause stigma, psychosocial and decreasing the productivity of patients and their families.
In accordance with the WHO global programme to eliminate the disease by 2020, countries that have LF problems, including Indonesia, must make systematic and integrated efforts to achieve elimination according to the global target. There are two strategies undertaken to achieve this goal, namely: stop the chain of transmission with the administration of the Preventive Chemotherapry (PC) medicine for all popultion in endemic areas by using a combination of Diethylcarbamazune (DEC) and Albendazole (Alb) once a year for a minimum of 5 consecutive years and efforts to prevent and limit the disability through the Morbidity Management and Disability Prevention (MMDP).
There are 118 out of 236 endemic districts that still carry out LF-MDA in 2019. It means that to achieve the target of LF elimination by 2020 Indonesia is still facing challenges as follows: 1) There will be 4 districts/cities that have only begun LF-MDA in 2017 and they will complete 5 effective rounds of LF-MDA in 2021; 2). Some endemic districts in Indonesia especially with difficult geographical areas are unamble to meet minimum effective coverage of LF-MDS; and 3) Several districts that have completed 5 rounds of LF-MDA still found microfilaria rates >1% and should repeat 2 rounds of LF-MDA.
The development of macrophilaricidal drugs that are more effective, safer, and can be used in the field, has been sought and researched for decades. So that, in 2018 WHO recommended the use of IDA regimens in LF-MDA that can be used as alternative regimens for countries currently using DA regimens in LF elimination programme and to overcome technical challenges that have been identified previously, such as failures in the transmission evaluation survey.
In 2020, IDA will be introduced in 3 districs in Indonesia, namely Pekalongan District (Central Java Province), Mamuju District (West Sulawesi Province), and Pekalongan City (Central Java Province). To ensure high quality MDA, it is necessary to support health authorities at district level and obtain commitment from policy makers in allocating adequate resources to implement LF- MDA using the IDA regimen.
Objective, scope of works 1. To identify an expert team or institution that are able to work together with the relevant departments at district level, to establisgh a network when preparing LF-MDA, conducting consultations and supervisions during LF-MDA, and leading the implementation of MDA evaluation survey 2. To obtain commitment from policy makers as well as related cross-program and cross-sectors for the implementation of LF- MDA with triple regimens to achieve 100% geographical coverage; 3. To prepare the implementation of LF-MDA with IDA regimens to achieve minimum coverage of least 65% of the total population; 4. To prepare adequate implementation, supervision, monitoring & evaluation plan for LF-MDA with IDA regimen.
Scope of Works: 1. Technical Meeting for Health Cadres and Health Workers for the Implementation of LF-MDA with IDA Regimen and the Prevention of Adverse Event Objectives: • To identify the preparadness of all puskesmas in Pekalongan District for the implementation of the LF-MDA with the IDA regimen; • To provide information on the stages of implementing the LF-MDA with the IDA regimen to health workers and health cadres representing all puskesmas in Pekalongan District; • To provide socialization on data collection and screening of targets in implementing LF-MDA with IDA regimens to health workers and health cadres representing all puskesmas in Pekalongan District; • To provide socialization of recording and reporting in the implementation of LF-MDA with IDA regimens to health workers and health cadres representatives from all puskesmas in Pekalongan District;
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 7 8 Unit Name NTD Unit-WHO Indonesia
• To providing socialization for the prevention of follow-up events after taking filariasis medicine in the implementation of the LF-MDA with IDA regimens to health workers and health cadres representing all puskesmas in Pekalongan District.
Outputs: • To obtain commitment from health workers and health cadres representing all puskesmas in Pekalongan District to ensure the successful of implementation of LF-MDA with the IDA regimen; • To obtain health workers and health cadres representing all puskesmas in Pekalongan District who are able to carry out data collection and screening of targets during the implementation of LF-MDA with the IDA regimen in accordance with existing procedures; • To obtain health workers and health cadres representing all puskesmas in Pekalongan District who are able to administer drugs as targeted in the implementation of the LF-MDA with the IDA regimen in accordance with existing procedures; • To obtain health workers and health cadres representing all puskesmas in Pekalongan District who are able to carry out the recording and reporting of LF-MDA implementation with the IDA regimen in accordance with existing procedures; • To obtain health workers and health cadres representing all puskesmas in Pekalongan District who are able to carry out countermeasures for the aftermath of taking medication for filariasis in the implementation of LF-MDA with the IDA regimen according to existing procedures. Methods: • The meeting is held face-to-face by carrying out the following health procedures: • Resource person and participants use surgical masks; • The distance between the resource person and participants and the distance between each participant is at least 1 meter. • The meeting will be held in two consecutive days. • This interactive meeting will be preceded by the presentation of the speakers, followed by discussion and role-playing at the end of the activity. The expected resource persons are : • Member of Kapfi • Member of NTF • Director of VBZDC • Head of Pekalongan District Health Office • Representative of Sub-Directorate of Filariasis and Helminthiasis • Representative of CENTRAL JAVA PHO • The meeting participants will be: • Regional leaders and policy makerd in Pekalongan District; • Cross-sectoral and cross-program officials in Pekalongan District; • Head of Pekalongan Health Service; • Division Heads within the Pekalongan District Health Office; • Manager of the filariasis program and all staff of the P2P Division of the Health Service in Pekalongan District; • Head of Puskesmas in Pekalongan District; • Managers of the puskesmas filariasis program in Pekalongan District; • Health cadres representing each puskesmas in Pekalongan District
2. Coverage Evaluation Survey Objectives: • To determine if the target coverage threshold has been met • To validate the reported coverage Outputs: • Estimation of PC coverage – to obtain a precise estimate of PC coverage that can be compared with the target coverage threshold to determine if the MDA was effective. • Validation of reported coverage – to check the accuracy of the data recording and reporting system and take corrective actions where necessary. • Identifying reasons for non-compliance – by identifying common reasons for not swallowing the drugs, programme managers can improve social mobilization prior to the next MDA round.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 8 9 Unit Name NTD Unit-WHO Indonesia
• Detecting problems with the supply chain and distribution systems – can identify clusters of individuals for whom the drugs were never offered and corrective action can be taken • Measuring coverage in specific population: subpopulations, e.g.. Rural vs. urban
Duration of assignment: 1 March 2020 – 31 May 2020 (3 months)
Expected Result and Reporting Expected Results/Outcomes: 1. District can achieve 100% geographical coverage of LF-MDA with IDA regimen 2. District can achieve at least 65% of epidemiological coverage of LF-MDA with IDA regimen 3. Severe adverse events related with LF-MDA with IDA regimen can be managed accordingly based on the SOP 4. Reported coverage is validated with the result of coverage evaluation survey
Expected Output: A. Progress Report (should be submitted to WHO in 6 weeks after the contract signature) 1. Result of Coordination and Socialization Meetings for the Implementation of triple Drugs MDA
B. Final Report (should be submitted to WHO by the end of contract period) 1. Final draft report approved by the National LF Elimination Programme and WHO peer review team that contains the summary or result of: (1) technical meeting with health cadre and health workers and (2) coverage evaluation survey 2. Statement of Expenditure
Profile of the Ideal Candidate • Expert teams must come from institutions that are registered as legal entities in Indonesia. • It must be a national institution (from Indonesia) that have a strong capacity in public health, infectious diseases, and have an understanding of the implementation of mass drugs administration for LF. • The expert team must consist of at least one senior public health specialist and one junior public health specialist, as evidenced by previous degrees in related fields and their CVs and publications. • Team members understand the characteristics of local community acceptance of health programs in Central Java Province • Team members have experience in monitoring and evaluation activities during PC medicine administration for LF • Team members are not state civil servants (ASN)
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 9 10 Unit Name NTD Unit-WHO Indonesia
Annex 2: Vendor Information Form
Company Information to be provided by the Vendor submitting the proposal UNGM Vendor ID Number: If available – Refer to WHO website for registration process* Legal Company Name: (Not trade name or DBA name) Company Contact: Address: City: State: Country: Zip: Telephone Number: Fax Number: Email Address: Company Website: Corporate information: Company mission statement Service commitment to customers and measurements used (if available)
Organization structure (include description of those parts of your organization that would be involved in the performance of the work)
Relevant experience (how could your expertise contribute to WHO’s needs for the purpose of this RFP) – Please attach reference and contact details Staffing information
______* http://www.who.int/about/finances-accountability/procurement/en/
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 10 11 Unit Name NTD Unit-WHO Indonesia
Annex 3: Contractual Provisions
Within 30 days of receipt of the contract between WHO and the successful bidder (the “Contract”), the successful bidder shall sign and date the Contract and return it to WHO according to the instructions provided at that time. If the bidder does not accept the Contract terms without changes, then WHO has the right not to proceed with the selected bidder and instead contract with another bidder of its choice. The Contract will include, without limitation, the provisions set forth below (with the successful bidder referred to below as the “Contractor”):
1. Compliance with WHO Codes and Policies. By entering into the Contract, the Contractor acknowledges that it has read, and hereby accepts and agrees to comply with, the WHO Policies (as defined below).
In connection with the foregoing, the Contractor shall take appropriate measures to prevent and respond to any violations of the standards of conduct, as described in the WHO Policies, by its employees and any other persons engaged by the Contractor to perform any services under the Contract.
Without limiting the foregoing, the Contractor shall promptly report to WHO, in accordance with the terms of the applicable WHO Policies, any actual or suspected violations of any WHO Policies of which the Contractor becomes aware.
For purposes of the Contract, the term “WHO Policies” means collectively: (i) the WHO Code of Ethics and Professional Conduct; (ii) the WHO Policy on Sexual Exploitation and Abuse Prevention and Response; (iii) the WHO Code of Conduct for responsible Research; (iv) the WHO Policy on Whistleblowing and Protection Against Retaliation; and (v) the UN Supplier Code of Conduct, in each case, as amended from time to time and which are publicly available on the WHO website at the following links: http://www.who.int/about/finances- accountability/procurement/en/ for the UN Supplier Code of Conduct and at http://www.who.int/about/ethics/en/ for the other WHO Policies.
2. Zero tolerance for sexual exploitation and abuse. WHO has zero tolerance towards sexual exploitation and abuse. In this regard, and without limiting any other provisions contained herein:
(i) each legal entity Contractor warrants that it will: (i) take all reasonable and appropriate measures to prevent sexual exploitation or abuse as described in the WHO Policy on Sexual Exploitation and Abuse Prevention and Response by any of its employees and any other persons engaged by it to perform any services under the Contract; and (ii) promptly report to WHO and respond to, in accordance with the terms of the Policy, any actual or suspected violations of the Policy of which the contractor becomes aware; and
(ii) each individual Contractor warrants that he/she will (i) not engage in any conduct that would constitute sexual exploitation or abuse as described in the WHO Policy on Sexual Exploitation and Abuse Prevention and Response; and (ii) promptly report to WHO, in accordance with the terms of the Policy, any actual or suspected violations of the Policy of which the Contractor becomes aware.
3. Tobacco/Arms Related Disclosure Statement. The Contractor may be required to disclose relationships it may have with the tobacco and/or arms industry through completion of the WHO Tobacco/Arms Disclosure Statement. In the event WHO requires completion of this Statement, the Contractor undertakes not to permit work on the Contract to commence, until WHO has assessed the disclosed information and confirmed to the Contractor in writing that the work can commence.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 11 12 Unit Name NTD Unit-WHO Indonesia
4. Anti-Terrorism and UN Sanctions; Fraud and Corruption. The Contractor warrants for the entire duration of the Contract that: i. it is not and will not be involved in, or associated with, any person or entity associated with terrorism, as designated by any UN Security Council sanctions regime, that it will not make any payment or provide any other support to any such person or entity and that it will not enter into any employment or subcontracting relationship with any such person or entity; ii. it shall not engage in any illegal, corrupt, fraudulent, collusive or coercive practices (including bribery, theft and other misuse of funds) in connection with the execution of the Contract; and iii. the Contractor shall take all necessary precautions to prevent the financing of terrorism and/or any illegal corrupt, fraudulent, collusive or coercive practices (including bribery, theft and other misuse of funds) in connection with the execution of the Contract.
Any payments used by the Contractor for the promotion of any terrorist activity or any illegal, corrupt, fraudulent, collusive or coercive practice shall be repaid to WHO without delay.
5. Breach of essential terms. The Contractor acknowledges and agrees that each of the provisions of paragraphs 1, 2, 3 and 4 above constitutes an essential term of the Contract, and that in case of breach of any of these provisions, WHO may, in its sole discretion, decide to: i. terminate the Contract, and/or any other contract concluded by WHO with the Contractor, immediately upon written notice to the Contractor, without any liability for termination charges or any other liability of any kind; and/or ii. exclude the Contractor from participating in any ongoing or future tenders and/or entering into any future contractual or collaborative relationships with WHO.
WHO shall be entitled to report any violation of such provisions to WHO’s governing bodies, other UN agencies, and/or donors.
6. Use of WHO Name and Emblem. Without WHO’s prior written approval, the Contractor shall not, in any statement or material of an advertising or promotional nature, refer to the Contract or the Contractor’s relationship with WHO, or otherwise use the name (or any abbreviation thereof) and/or emblem of the World Health Organization.
7. Assurances regarding procurement. If the option for payment of a maximum amount applies, to the extent the Contractor is required to purchase any goods and/or services in connection with its performance of the Contract, the Contractor shall ensure that such goods and/or services shall be procured in accordance with the principle of best value for money. "Best value for money" means the responsive offer that is the best combination of technical specifications, quality and price.
8. Audit. WHO may request a financial and operational review or audit of the work performed under the Contract, to be conducted by WHO and/or parties authorized by WHO, and the Contractor undertakes to facilitate such review or audit. This review or audit may be carried out at any time during the implementation of the work performed under the Contract, or within five years of completion of the work. In order to facilitate such financial and operational review or audit, the Contractor shall keep accurate and systematic accounts and records in respect of the work performed under the Contract.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 12 13 Unit Name NTD Unit-WHO Indonesia
The Contractor shall make available, without restriction, to WHO and/or parties authorized by WHO: i. the Contractor’s books, records and systems (including all relevant financial and operational information) relating to the Contract; and ii. reasonable access to the Contractor’s premises and personnel.
The Contractor shall provide satisfactory explanations to all queries arising in connection with the aforementioned audit and access rights.
WHO may request the Contractor to provide complementary information about the work performed under the Contract that is reasonably available, including the findings and results of an audit (internal or external) conducted by the Contractor and related to the work performed under the Contract.
9. Publication of Contract. Subject to considerations of confidentiality, WHO may acknowledge the existence of the Contract to the public and publish and/or otherwise publicly disclose the Contractor’s name and country of incorporation, general information with respect to the work described herein and the Contract value. Such disclosure will be made in accordance with WHO’s Information Disclosure Policy and shall be consistent with the terms of the Contract.
015-2021 Doc. Ref: RFP_LowValue_V.02 2018_20180419 pg. 13 Technical Support for the Implementation of Mass Drugs Administration with Triple Drugs Ivermectin, Diethylcarbamazine, and Albendazole (IDA) in Pekalongan City, Central Java Province, 2020
Name of institution Duration: 1 March - 31 May 2021 (3 months)
No Activities Person/Unit Loc Time Unit Cost Subtotal (IDR) Subtotal (USD) 1 Professional fee Team leader Field officers Admin support … (other, specified) 2 Technical Meeting for HWs/Cadres Local transport Daily allowance Meeting package (if required) Resource person fee … (other, specified) 3 Coverage Evaluation Survey Transport vv Terminal allowance (if needed) Local transport for district participant Daily allowance Meeting package (if required) Resource person fee … (other, specified) 5 IT Equipment and logistic
6 Others Stationary Photocopy … (other, specified)
Total Grand Total STANDAR BIAYA UMUM (SBU) 2019 Berdasarkan PMK No. 32/PMK.02/2018 KHUSUS SEWA GEDUNG DAN KONSUMSI RAPAT
PENGINAPAN UANG HARIAN PAKET PERTEMUAN PAKET MEETING TIKET PESAWAT PP JKT UANG DALAM KOTA KONSUMSI HARIAN > 8 JAM SEWA (termasuk SEWA KENDARAAN FULLBOARD FULLDAY/ NO PROV IBU KOTA PERJALANAN PEJABAT ES.III/ PEJABAT ES.IV/ (RODA 4) TAXI FULLBOARD Kota ESELON I ESELON II GOL II/ GOL I DALAM HALFDAY HALFDAY FULLDAY FULLBOARD GEDUNG DINAS LUAR perjalanan PP GOL. IV GOL. III MAKAN SNACK Bisnis Ekonomi LUAR KOTA DALAM Tujuan KOTA ke Lokasi) KOTA KOTA 1 ACEH Banda Aceh 360,000 140,000 4,420,000 3,526,000 1,294,000 556,000 556,000 795,000 123,000 120,000 120,000 85,000 300,000 330,000 772,000 10,831,000 51,000 19,000 Banda Aceh 7,519,000 4,492,000 2 SUMUT Medan 370,000 150,000 4,960,000 1,518,000 1,100,000 530,000 530,000 888,000 232,000 130,000 130,000 95,000 178,000 275,000 746,000 17,188,000 47,000 17,000 Medan 7,252,000 3,808,000 3 RIAU Pekanbaru 370,000 150,000 3,820,000 3,119,000 1,650,000 852,000 852,000 875,000 94,000 130,000 130,000 85,000 185,000 245,000 591,000 10,964,000 40,000 16,000 Pekanbaru 5,583,000 3,016,000 4 KEPRI Tj. Pinang 370,000 150,000 4,275,000 1,854,000 1,037,000 792,000 792,000 820,000 137,000 130,000 130,000 95,000 227,000 273,000 625,000 7,843,000 41,000 25,000 Batam 4,867,000 2,888,000 5 JAMBI Jambi 370,000 150,000 4,000,000 3,337,000 1,212,000 520,000 520,000 710,000 147,000 130,000 130,000 95,000 215,000 301,000 840,000 11,250,000 42,000 17,000 Jambi 4,065,000 2,460,000 6 SUMBAR Padang 380,000 150,000 5,236,000 3,332,000 1,353,000 650,000 650,000 700,000 190,000 120,000 120,000 85,000 173,000 240,000 663,000 17,620,000 44,000 17,000 Padang 5,530,000 2,952,000 7 SUMSEL Palembang 380,000 150,000 5,850,000 3,083,000 1,571,000 861,000 861,000 1,094,000 128,000 120,000 120,000 85,000 218,000 293,000 745,000 15,407,000 46,000 17,000 Palembang 3,861,000 2,268,000 8 LAMPUNG Bdr. Lampung 380,000 150,000 4,491,000 2,067,000 1,140,000 400,000 400,000 764,000 167,000 130,000 130,000 95,000 216,000 270,000 640,000 10,000,000 40,000 20,000 Bdr. Lampung 2,407,000 1,583,000 9 BENGKULU Bengkulu 380,000 150,000 2,071,000 1,628,000 1,546,000 572,000 572,000 710,000 109,000 130,000 130,000 95,000 214,000 284,000 912,000 8,250,000 44,000 16,000 Bengkulu 4,364,000 2,621,000 10 BABEL Pangkal Pinang 410,000 160,000 3,827,000 2,838,000 1,957,000 622,000 622,000 1,159,000 90,000 130,000 130,000 95,000 299,000 385,000 804,000 11,407,000 40,000 18,000 Pangkal Pinang 3,412,000 2,139,000 11 BANTEN Serang 370,000 150,000 5,725,000 2,373,000 1,000,000 718,000 718,000 700,000 446,000 120,000 120,000 85,000 275,000 354,000 837,000 13,063,000 54,000 19,000 ‐ 12 JABAR Bandung 430,000 170,000 5,381,000 2,755,000 1,006,000 570,000 570,000 845,000 166,000 150,000 150,000 105,000 331,000 398,000 822,000 23,438,000 45,000 20,000 ‐ 13 DKI JAKARTA Jakarta 530,000 210,000 8,720,000 1,490,000 992,000 610,000 610,000 800,000 256,000 180,000 180,000 130,000 354,000 433,000 1,197,000 30,773,000 47,000 22,000 ‐ 14 JATENG Semarang 370,000 150,000 4,242,000 1,480,000 954,000 486,000 486,000 875,000 75,000 130,000 130,000 95,000 191,000 263,000 675,000 13,125,000 38,000 15,000 Semarang 3,861,000 2,182,000 Solo 3,861,000 2,342,000 15 DIY Yogyakarta 420,000 170,000 5,017,000 2,695,000 1,384,000 845,000 845,000 799,000 118,000 140,000 140,000 100,000 210,000 310,000 750,000 13,747,000 36,000 15,000 Jogyakarta 4,107,000 2,268,000 16 JATIM Surabaya 410,000 160,000 4,400,000 1,605,000 1,076,000 664,000 664,000 875,000 194,000 140,000 140,000 100,000 338,000 395,000 1,352,000 15,782,000 44,000 23,000 Surabaya 5,466,000 2,674,000 Malang 4,599,000 2,695,000 17 BALI Denpasar 480,000 190,000 4,890,000 1,946,000 990,000 910,000 910,000 790,000 159,000 160,000 160,000 115,000 330,000 441,000 1,182,000 15,000,000 48,000 20,000 Denpasar 5,305,000 3,262,000 18 NTB Mataram 440,000 180,000 3,500,000 2,648,000 1,418,000 580,000 580,000 790,000 231,000 150,000 150,000 105,000 280,000 420,000 764,000 9,250,000 41,000 17,000 Mataram 5,316,000 3,230,000 19 NTT Kupang 430,000 170,000 3,000,000 1,493,000 1,355,000 550,000 550,000 800,000 108,000 140,000 140,000 100,000 271,000 377,000 825,000 8,705,000 41,000 21,000 Kupang 9,413,000 5,081,000 20 KALBAR Pontianak 380,000 150,000 2,654,000 1,538,000 1,125,000 538,000 538,000 798,000 135,000 130,000 130,000 95,000 250,000 331,000 664,000 10,835,000 44,000 16,000 Pontianak 4,353,000 2,781,000 21 KALTENG Palangkaraya 360,000 140,000 4,901,000 3,391,000 1,160,000 659,000 659,000 1,029,000 111,000 120,000 120,000 85,000 242,000 340,000 1,031,000 9,375,000 40,000 15,000 Palangkaraya 4,984,000 2,984,000 22 KALSEL Banjarmasin 380,000 150,000 4,797,000 3,316,000 1,500,000 540,000 540,000 710,000 150,000 130,000 130,000 95,000 194,000 295,000 734,000 10,710,000 45,000 15,000 Banjarmasin 5,252,000 2,995,000 23 KALTIM Samarinda 430,000 170,000 4,000,000 2,188,000 1,507,000 804,000 804,000 1,013,000 450,000 150,000 150,000 105,000 207,000 302,000 750,000 10,594,000 43,000 24,000 Balikpapan 7,412,000 3,797,000 24 KALTARA Tanjung Selor 430,000 170,000 4,000,000 2,188,000 1,507,000 804,000 804,000 1,013,000 102,000 150,000 150,000 105,000 207,000 302,000 750,000 9,625,000 43,000 20,000 Tarakan 7,412,000 3,797,000 25 SULUT Manado 370,000 150,000 4,919,000 2,290,000 924,000 782,000 782,000 888,000 138,000 130,000 130,000 95,000 185,000 270,000 737,000 18,400,000 55,000 25,000 Manado 10,824,000 5,102,000 26 GORONTALO Gorontalo 370,000 150,000 4,168,000 2,549,000 1,431,000 764,000 764,000 740,000 240,000 130,000 130,000 95,000 175,000 250,000 1,299,000 9,296,000 44,000 14,000 Gorontalo 7,231,000 4,824,000 27 SULBAR Mamuju 410,000 160,000 4,076,000 2,581,000 1,075,000 704,000 704,000 710,000 313,000 120,000 120,000 85,000 235,000 323,000 792,000 7,200,000 47,000 20,000 Mamuju 7,295,000 4,867,000 28 SULSEL Makassar 430,000 170,000 4,820,000 1,550,000 1,020,000 665,000 665,000 700,000 145,000 150,000 150,000 105,000 206,000 320,000 1,127,000 11,132,000 48,000 24,000 Makassar 7,444,000 3,829,000 29 SULTENG Palu 370,000 150,000 2,309,000 2,027,000 1,567,000 951,000 951,000 770,000 165,000 130,000 130,000 95,000 234,000 385,000 738,000 13,344,000 41,000 17,000 Palu 9,348,000 5,113,000 30 SULTRA Kendari 380,000 150,000 2,475,000 2,059,000 1,297,000 786,000 786,000 770,000 171,000 130,000 130,000 95,000 195,000 295,000 688,000 14,063,000 42,000 20,000 Kendari 7,658,000 4,182,000 31 MALUKU Ambon 380,000 150,000 3,467,000 3,240,000 1,048,000 667,000 667,000 890,000 240,000 120,000 120,000 85,000 253,000 346,000 724,000 8,000,000 59,000 22,000 Ambon 13,285,000 7,081,000 32 MALUT Sofii 430,000 170,000 3,440,000 3,175,000 1,073,000 480,000 480,000 900,000 215,000 130,000 130,000 95,000 169,000 354,000 669,000 8,000,000 63,000 23,000 Ternate 10,001,000 6,664,000 33 PAPUA Jayapura 580,000 230,000 3,859,000 3,318,000 2,521,000 829,000 829,000 1,025,000 431,000 200,000 200,000 140,000 293,000 478,000 990,000 15,000,000 60,000 31,000 Jayapura 14,568,000 8,193,000 Biak 14,065,000 7,519,000 Timika 13,830,000 7,487,000 34 PAPUA BARAT Manokwari 480,000 190,000 3,872,000 3,212,000 2,056,000 600,000 600,000 980,000 182,000 160,000 160,000 115,000 284,000 421,000 1,120,000 18,350,000 62,000 25,000 Manokwari 16,226,000 10,824,000
406,765 161,765 4,281,824 2,453,206 1,319,000 672,382 844,853 187,000 137,059 137,059 98,088 239,235 332,324 839,853 12,869,618 46,029 19,559 7,411,059 4,235,294 407,000 162,000 780,000 516,000 771,000 145,000 137,000 115,000 98,000 204,000 297,000 639,000 11,116,000 44,000 17,000
4,858,000 2,803,000
185 ANNEX
Technical Support for the Implementation of Mass Drugs Administration with Triple Drugs Ivermectin, Diethylcarbamazine, and Albendazole (IDA) in Pekalongan City, Central Java Province, 2021
EVALUATION CRITERIA
MAX. MIN. CATEGORY POINTS PASS POINTS 1. ORGANIZATIONAL CAPACITY 15
1.1 Institution/company profile indicating major work, with justification of why the 4 institution is well suited to the assignment.
1.2 Detail of relevant experience including work related in public health and list of 3 clients in the last five years, including contact details (name, email address, and phone numbers that can be used as reference)
1.3 Proven knowledge and previous work in LF Elimination programme or mass 8 drugs administration (MDA), especially in monitoring and evaluation of MDA activities
2. QUALITY OF THE TECHNICAL PROPOSAL 40
2.1 Proposed methodology and approach with reference to objectives in TOR, 20 Including: • Proposed a concept focus to the training/technical meeting for health workers and cadres on the field • Proposed a concept and methodology focus to the coverage evaluation survey
2.2 Implementation timeline: identify key tasks and timeline, focal person for each 10 activity/deliverable should be identified.
2.3 Anticipated project risks and mitigation measures as well as quality assurance 10
3. KEY PERSONNEL 15
3.1 Names and full CVs of the institution personnel that will be directly involved in the consultancy, including (but not limited to) the designated Team Leader/ Project Manager, Crew / Talents. a. The list should include at least one staff / consultant with background of public health and has recognized reputation or experienced in LF Elimination Programme, proven by report.
b. Adequate and appropriate staff combination in relation to the respective tasks and deliverables (see TOR); and relevant prior experiences of similar scope and complexity.
c. The team member of institution/organization should consist of: - 1 team leader/manager - 2 field officers - 1 admin support member
TECHNICAL PROPOSAL 70 50
PRICE PROPOSAL 30
TOTAL MARKS 100
SELF DECLARATION FOR M Applicable to private and public companies
Entity Name: …………………………………………………………………………………………………
………………………………………………………………………………………………… Mailing Address: ………………………………………………………………………………………………… …………………………………………………………………………………………………
Name and Title of duly authorized representative: …………………………………………………………………………………………………
Date: …………………………………………………………………………………………………
Signature: …………………………………………………………………………………………………
Annex 7 - Proposal Completeness Form Please ensure that the following document are submitted. Annex 2, Self-Declaration Form and Legal Document are to be submitted along with the technical proposal in the technical proposal envelope.
RFP No. and Title of Activity: …………………………………………………………………………………………………………………………………………………………………………………. …………………………………………………………………………………………………………………………………………………………………………………
Completed in full Section Requirement (Yes/No) Annex 2 Vendor Information Form ☐ Yes ☐ No Self-Declaration Form ☐ Yes ☐ No Legal Document for Operation Permit in Indonesia ☐ Yes ☐ No Technical Proposal ☐ Yes ☐ No Financial Proposal ☐ Yes ☐ No
The enclosed proposal is valid for ______days* from the date of this form. * minimum period of 180 calendar days after the closing date for submission of proposals.
Agreed and accepted,
Entity Name: …………………………………………………………………………………………………
………………………………………………………………………………………………… Mailing Address: ………………………………………………………………………………………………… ………………………………………………………………………………………………… Name and Title of duly authorized representative: …………………………………………………………………………………………………
Signature:
Date: …………………………………………………………………………………………………